DAWN - Day One Biopharmaceuticals, Inc.
IEX Last Trade
12.795
0.005 0.039%
Share volume: 18,910
Last Updated: Fri 27 Dec 2024 08:30:32 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$12.79
0.01
0.04%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
1.65%
1 Month
-5.98%
3 Months
-8.90%
6 Months
-6.72%
1 Year
-14.68%
2 Year
-33.30%
Key data
Stock price
$12.80
DAY RANGE
$12.49 - $12.85
52 WEEK RANGE
$12.47 - $18.07
52 WEEK CHANGE
-$11.64
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Jeremy Bender
Region: US
Website: dayonebio.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: dayonebio.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Day One Biopharmaceuticals, Inc. develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor.
Recent news